In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Germany: Europe’s Go-To Market Changes Rules For High-Risk And Promising Devices

Executive Summary

Several recent changes to the German health care system will significantly influence the market access climate for medical device companies working in Europe’s largest market. Do they represent an opportunity or a threat for manufacturers accessing the market?

You may also be interested in...

Industry Sees Much To Improve In Germany's New High-Risk Medtech Assessment Scheme

Only two of eight treatments passed muster under Germany's new NUBs scheme for assessing the benefit of high-risk products for inpatient use. As with the country's outpatient assessment counterpart, industry is pushing for changes.

Germany – Still Europe's Stand-Out Medtech Innovation Market

Germany's introduction of benefit assessments for class IIb and class III medical devices, and the impending EU Medical Device and IVD Regulations will place an unquantified strain on medtech manufacturers in Europe's largest market. But new innovation schemes are adding more dimensions for businesses locally.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts